Specific Phobias

DSM-5 Diagnostic Criteria

To meet criteria for specific phobia (300.29 / F40.2xx), all of the following must be present:

• Criterion A: Marked fear or anxiety about a specific object or situation (e.g., flying, heights, animals, receiving an injection, seeing blood). In children, fear may be expressed by crying, tantrums, freezing, or clinging.
• Criterion B: The phobic object or situation almost always provokes immediate fear or anxiety.
• Criterion C: The phobic object or situation is actively avoided or endured with intense fear or anxiety.
• Criterion D: The fear or anxiety is out of proportion to the actual danger posed and to the sociocultural context.
• Criterion E: The fear, anxiety, or avoidance is persistent, typically lasting six months or more.
• Criterion F: The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.
• Criterion G: The disturbance is not better explained by another mental disorder, such as agoraphobia, OCD, PTSD, separation anxiety disorder, or social anxiety disorder.

The Five DSM-5 Subtypes

1. Animal Type

• Examples: spiders (arachnophobia), dogs (cynophobia), snakes (ophidiophobia), insects, rodents
• Most common subtype; typically childhood onset
• Strong female predominance (roughly 4:1)
• Often acquired through observational learning or direct conditioning

2. Natural Environment Type

• Examples: heights (acrophobia), storms (astraphobia), water (aquaphobia), darkness
• Typically begins in childhood
• May reflect evolutionarily prepared fears
• Acrophobia is the most prevalent within this subtype

3. Blood-Injection-Injury (BII) Type

• Examples: needles (trypanophobia), blood (hemophobia), invasive medical procedures, dental work
• Unique vasovagal physiology: initial sympathetic arousal followed by parasympathetic crash, often producing fainting (50–80% of cases)
• Strong genetic loading; high familial aggregation
• Requires modified exposure protocols (applied tension technique) due to fainting risk

4. Situational Type

• Examples: flying (aerophobia), enclosed spaces (claustrophobia), elevators, bridges, tunnels, driving
• Bimodal age of onset: childhood and mid-20s
• Most resembles panic disorder in symptom presentation
• Highest comorbidity with agoraphobia

5. Other Type

• Examples: choking, vomiting (emetophobia), contracting an illness, costumed characters, loud sounds
• In children: fear of clowns or characters
• Heterogeneous category for fears not fitting the other four subtypes

Differential Diagnosis

Specific phobia must be distinguished from other anxiety presentations:

• Agoraphobia: Fear involves multiple situations from which escape would be difficult, not a single circumscribed stimulus. See agoraphobia.
• Social Anxiety Disorder: Fear is specifically of social scrutiny or negative evaluation.
• OCD: Avoidance is driven by obsessions (e.g., contamination), not the object itself.
• PTSD: Avoidance is tied to a specific traumatic event and accompanied by re-experiencing symptoms. See trauma and PTSD.
• Separation Anxiety Disorder: Fear is of separation from attachment figures. See separation anxiety disorder.
• Illness Anxiety Disorder: Preoccupation is with having or acquiring a serious illness. See illness anxiety disorder.

Etiology and Risk Factors

Genetic and Temperamental

• Heritability estimates: 30–40% for specific phobia overall
• BII type shows the strongest genetic loading (~60%)
• Behavioral inhibition in childhood is a robust risk factor
• Negative affectivity (neuroticism) increases vulnerability

Environmental and Learning Pathways

• Direct conditioning: Traumatic encounter with the phobic stimulus
• Vicarious learning: Observing fear in others, particularly parents
• Informational transmission: Hearing warnings or media depictions
• Non-associative pathway: Innate, evolutionarily prepared fears (e.g., snakes, heights)

Neurobiology

• Hyperactive amygdala response to phobic stimuli
• Reduced prefrontal regulation of fear circuits
• Impaired fear extinction learning

Clinical Assessment

Standardized Instruments

• Fear Survey Schedule (FSS-III): Self-report screen for common feared stimuli
• Anxiety Disorders Interview Schedule (ADIS-5): Structured diagnostic interview
• Behavioral Approach Test (BAT): Observed graded approach to phobic stimulus
• Subjective Units of Distress Scale (SUDS): 0–100 anxiety rating used during exposure

Key Clinical Questions

• Specific feared object or situation and triggering features
• Onset, course, and any precipitating events
• Avoidance behaviors and safety behaviors
• Functional impairment across domains
• Comorbid anxiety, mood, or substance use disorders
• For BII type: history of fainting episodes

Evidence-Based Treatment

Exposure Therapy (First-Line)

Exposure therapy is the most efficacious treatment for specific phobia, with response rates of 80–90% and durable gains at long-term follow-up. Variants include:

• In vivo exposure: Direct, graded contact with the feared stimulus
• Imaginal exposure: Vivid mental rehearsal when in vivo is impractical
• Virtual reality (VR) exposure: Effective for flying, heights, and animal phobias
• One-session treatment (OST): Single 3-hour intensive session, evidence-based for several subtypes
• Interoceptive exposure: Used when somatic sensations themselves are feared (e.g., choking phobia)

Specialized Approach: Applied Tension for BII

Because BII phobia involves vasovagal fainting, standard exposure can backfire. The applied tension protocol teaches patients to tense large muscle groups during exposure, raising blood pressure and preventing syncope. Combined with exposure, applied tension is the gold standard for BII phobia.

Cognitive-Behavioral Therapy

• Cognitive restructuring of catastrophic appraisals
• Psychoeducation about the fear response
• Behavioral experiments to disconfirm threat predictions

Pharmacotherapy

• No medications are FDA-approved as monotherapy for specific phobia
• Short-term benzodiazepines may be used situationally (e.g., flying), but interfere with exposure learning
• D-cycloserine has shown modest augmentation effects on exposure therapy
• Beta-blockers occasionally used for performance-related fears

Self-Help and Digital Interventions

• Self-directed exposure manuals show moderate efficacy
• VR apps and smartphone-delivered exposure are emerging options

Course and Prognosis

• Childhood-onset phobias may remit spontaneously in up to 25% of cases
• Adult-onset phobias tend to be chronic without treatment
• Comorbidity with anxiety, mood, and substance use disorders is common (~50–80%)
• Treated patients typically maintain gains for years following exposure therapy
• Untreated specific phobia is associated with reduced educational and occupational attainment

Special Populations

Children and Adolescents

• Developmentally normal fears (e.g., dark, monsters) must be differentiated from phobia
• Parent involvement enhances treatment outcomes
• One-session treatment has strong evidence in youth

Older Adults

• Phobias may interfere with medical care (BII subtype especially)
• Falls-related acrophobia is common after a fall
• Treatment efficacy is preserved across the lifespan

Pregnant and Perinatal Patients

• Tokophobia (fear of childbirth) and BII phobia have particular obstetric relevance
• Behavioral treatment is preferred to avoid medication exposure